Comparative Pharmacology
Head-to-head clinical analysis: GEMIFLOXACIN MESYLATE versus LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEMIFLOXACIN MESYLATE versus LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
GEMIFLOXACIN MESYLATE vs LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription.
Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.
320 mg orally once daily for 7-14 days
500 mg or 750 mg intravenously once daily. Infusion over 60-90 minutes.
None Documented
None Documented
Terminal elimination half-life 7–9 hours (mean 8.2 h) in healthy adults; prolonged in renal impairment (e.g., 15–22 h in severe renal impairment).
6-8 hours in patients with normal renal function (creatinine clearance >50 mL/min); increases to 20-48 hours in severe renal impairment (CrCl <20 mL/min); clinically relevant for dosing interval adjustment.
Renal: ~61% as unchanged drug, ~7% as glucuronide; Fecal/biliary: ~28% as unchanged drug and metabolites.
Renal: ~87% of dose excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5% eliminated as unchanged drug and metabolites; <4% recovered in feces.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic